Safety study of a targeted radiation medicine for CXCR4-positive lesions
Part of Cancer, Lungs & breathing clinical trials.
This early-phase study tests the safety of a targeted radiation treatment (212Pb-Pentixather) in people whose scans show a specific marker called CXCR4. It may help by delivering radiation to lesions that have this marker, but the main goal here is to check safety and dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent on your own (or meet the study’s consent rules).
- Your blood counts are strong enough: platelets, hemoglobin, and neutrophils must meet set minimums.
- Your kidneys and liver tests are within acceptable ranges.
- Your cancer/lesions must have at least one spot 2 cm or larger that is CXCR4-positive on a specific scan (Lead-203 Pentixather SPECT/CT).
- You recently must not have had major surgery (within 4 weeks) and must not have had other study medicines (within 4 weeks).
- You must not be pregnant or breastfeeding, and you must agree to birth-control rules during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
This trial is testing a new type of PET scan that uses a radioactive tracer called 68Ga-PentixaFor to see if it can better detect metastatic small cell lung cancer compared to standard scans. You may be eligible if you have newly diagnosed, untreated metastatic small cell lung cancer and are about to start your first treatment.
This trial looks at an imaging scan called CXCR4-targeted PET/CT to help doctors see certain blood cancers. You may be helped by getting clearer information about where cancer is in your body, and the results may guide future care.
This trial tests a new way to deliver radiation called SCINTIX that uses PET scans to target tumors more precisely. It is for people with certain solid tumors that are not in the bone or lungs.
This study tests a new imaging method called CXCR4 PET/CT that may help doctors better see and understand lymphomas (a type of blood cancer). It is for people who are newly diagnosed or suspected of having lymphoma and have already had a standard PET/CT.
This trial uses a special imaging scan (CXCR4 PET/CT) to help diagnose or evaluate certain diseases linked to a protein called CXCR4. It may offer more detailed information than standard scans.
Hear when a new Carcinoid Tumor Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.